COMMUNIQUÉS West-GlobeNewswire

Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial

26/06/2018 - 14:00

Iomab-B remains the only targeted conditioning treatment in clinical trials with the potential to increase access to and improve outcomes of bone marrow transplant NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- Actinium [...]

Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China

26/06/2018 - 14:00

- Agios to Receive $12 Million Upfront Payment and is Eligible to Receive Development, Regulatory, and Sales-Based Milestones and Tiered Royalties - - Collaboration Provides Opportunity for Patients with IDH1m Cancers [...]

PhaseBio Names Michael B. York as Vice President of Corporate Development and Commercial Strategy

26/06/2018 - 14:00

MALVERN, Pa., June 26, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for orphan diseases with an initial focus on [...]

Transplantation Pioneer Dr. Leonard Bailey Co-Founds ADiTx Therapeutics, Inc. to Develop Immune Modulation Treatment for Extending the Life of Transplanted Organs

26/06/2018 - 14:00

Novel ADi technology designed to therapeutically induce immune tolerance to transplanted tissues LOMA LINDA, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Founders and management comprised of scientific experts and [...]

aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate

26/06/2018 - 14:00

ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports Potential Once-Monthly Dosing SAN DIEGO, June 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE [...]

Nu-Med Plus, Inc. Selects s2s Public Relations firm as its Strategic Partner

26/06/2018 - 14:00

The firm specializes in driving investor interest SALT LAKE CITY, June 26, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc . (OTCQB:NUMD), a medical device company which investigates and develops nitric oxide applications of [...]

7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program

26/06/2018 - 14:00

HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a privately-held immunotherapy company focused on development of novel tumor-targeting cell adhesion agents, announced today the formation of its Scientific [...]

ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)

26/06/2018 - 14:00

― ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae ― ― ZEMDRI is the only once-daily aminoglycoside therapy approved for use in cUTI ― ― ZEMDRI has [...]

Precipio and Nucleai Partner to Develop Artificial Intelligence-Powered Hemepath Solution

26/06/2018 - 14:00

System will support Hematopathologists in accurately identifying abnormalities to ensure diagnostic accuracy NEW HAVEN, Conn., June 26, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO [...]

Arch Therapeutics Provides Skin Sensitization Study Status Update

26/06/2018 - 13:50

Approximately two-thirds of applications in the repeat dosing induction phase are completed; Study remains on track FRAMINGHAM, Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or [...]

SELLAS Life Sciences Announces Proposed Public Offering of Common Stock

26/06/2018 - 13:46

NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or “the Company”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range [...]

Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting

26/06/2018 - 10:00

Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting Leading cancer supportive care experts in oncology explore how to provide the best care for patients by discussing the importance [...]

Solon Eiendom ASA : Primary insider notification

26/06/2018 - 08:31

(Oslo, Norway, June 25, 2018) UFI AS has today bought 38.664 shares in Solon Eiendom ASA at a price of NOK 29.9097 per share. Solon Eiendom ASA Board Member Øystein A. Landvik owns 33,34 % of the shares in UFI AS. [...]

Shire plc : Rule 2.9 Announcement

26/06/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 26 June 2018 Shire [...]

IBT plans to start its phase 3 study in the second half of 2018 and contracts CRO

26/06/2018 - 08:00

IBT has previously announced its plan to start the phase 3 study in the first half of 2018. Preparations for the study have taken slightly longer than expected and the Company now plans to initiate the phase 3 study in [...]

FIT Biotech Oy: EHVA clinical trial authorization granted for testing FIT-06 in UK

26/06/2018 - 07:31

FIT Biotech Oy Company release 26.6.2018 at 8:30 AM EET EHVA clinical trial authorization granted for testing FIT-06 in UK FIT Biotech Oy ("Company", FITBIO: FN Finland) today announced that the UK medical authorities [...]

Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin

26/06/2018 - 07:16

Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also highlights that over 50% [...]

Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma

26/06/2018 - 07:16

Basel, Switzerland, June 26, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the first patient has been dosed in the phase 2a expansion part of Basilea's ongoing phase 1/2a clinical study with its [...]

Fagron NV: Disclosure of received notifications

26/06/2018 - 06:31

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 June 2018 - 6:30am (CET) Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron [...]